Chronic Myeloid Leukemia Market

Key Highlights

• As per the study Kiyotaka Yamazaki et al. (2020), Chronic Myeloid Leukemia is a myeloproliferative blood cancer, with an annual incidence in Japan of 0.5 cases per 100,000 population.

• According to NICE-UK, the annual incidence of Chronic Myeloid Leukemia is 4.2 cases per 100,000. In addition to that, Chronic Myeloid Leukemia represents only 5% of all childhood leukemia. It is also reported that 85-90% of patients are diagnosed in the chronic phase.

• Chronic Myeloid Leukemia epidemiology is segmented as Total Chronic Myeloid Leukemia Incident Cases, Total Chronic Myeloid Leukemia Symptomatic Cases, Cases of Chronic Myeloid Leukemia by Phases (Chronic, Accelerated, and Blast), Chronic Myeloid Leukemia Age-specific Cases, and Chronic Myeloid Leukemia Mutation-specific Cases in the Chronic Myeloid Leukemia market report.

Request for unlock CAGR of Chronic Myeloid Leukemia Market

DelveInsight's "Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Chronic Myeloid Leukemia, historical and forecasted epidemiology as well as the Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, Chronic Myeloid Leukemia market share of the individual therapies, current and forecasted Chronic Myeloid Leukemia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Chronic Myeloid Leukemia treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019–2032

Chronic Myeloid Leukemia Market Disease Understanding and Treatment Algorithm

The DelveInsight’s Chronic Myeloid Leukemia market report gives a thorough understanding of Chronic Myeloid Leukemia by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Chronic Myeloid Leukemia is also known as chronic myelogenous leukemia. It's a type of cancer that starts in certain blood-forming cells of the bone marrow. Chronic Myeloid Leukemia is a fairly slow growing leukemia, but it can change into a fast-growing acute leukemia that's hard to treat. The phases of Chronic Myeloid Leukemia are based on the number of immature white blood cells that are seen in the blood or bone marrow. The three phases of Chronic Myeloid Leukemia includes Chronic phase Chronic Myeloid Leukemia, Accelerated phase Chronic Myeloid Leukemia, and Blast phase Chronic Myeloid Leukemia.

People who have Chronic Myeloid Leukemia may not have any symptoms at first. Often, patients learn they have Chronic Myeloid Leukemia after a routine physical exam or a blood test. Chronic Myeloid Leukemia signs and symptoms tend to develop gradually which includes Weakness, Fatigue, Shortness of breath during basic everyday activities, Unexplained weight loss etc. Moreover, a shortage of normal white blood cells can increase a Chronic Myeloid Leukemia patient’s risk of infection, and a shortage of platelets can lead to excessive bruising or bleeding. Symptoms may also occur because Chronic Myeloid Leukemia cells collect in organs such as the spleen.

Chronic Myeloid Leukemia Diagnosis

There are certain tests that are used to diagnose Chronic Myeloid Leukemia which includes, Complete Blood Count (CBC) with Differential, this test is used to measure the number red blood cells, white blood cells and platelets in a sample of blood. Bone Marrow Aspiration and Biopsy, these tests are used to examine bone marrow cells to find abnormalities, and are generally done at the same time. The sample is usually taken from the patient’s hip bone after medicine has been given to numb the skin. Quantitative Polymerase Chain Reaction (qPCR) is the most sensitive test that detects and measures the quantity of the BCR-ABL1 gene in blood or bone marrow samples. It can detect very small amounts of the BCR-ABL1 gene to a level of one Chronic Myeloid Leukemia cell in a background of 100,000 to 1,000,000 normal cells.

Chronic Myeloid Leukemia Treatment

Tyrosine kinase inhibitor (TKI) therapy is standard treatment for chronic phase Chronic Myeloid Leukemia. TKIs are often successful at managing Chronic Myeloid Leukemia for long periods of time. The following TKIs are approved as primary treatment for chronic phase Chronic Myeloid Leukemia. Imatinib (Gleevec), Dasatinib (Sprycel), Nilotinib (Tasigna), Bosutinib (Bosulif), and others. Chemotherapy is generally used only in patients with blast phase disease as a way to get the Chronic Myeloid Leukemia back into chronic phase. Very high-dose chemotherapy is sometimes used in the protocol that prepares patients for an allogeneic stem cell transplantation. Some of the chemotherapy drugs include Omacetaxine mepesuccinate (Synribo) etc.

Asciminib (Scemblix) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ Chronic Myeloid Leukemia) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). This indication is approved under accelerated approval based on major molecular response (MMR).

Chronic Myeloid Leukemia Epidemiology

The Chronic Myeloid Leukemia epidemiology section provides insights about historical and current Chronic Myeloid Leukemia patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

• As per the study Kiyotaka Yamazaki et al. (2020), Chronic Myeloid Leukemia is a myeloproliferative blood cancer, with an annual incidence in Japan of 0.5 cases per 100,000 population.

• According to NICE-UK, the annual incidence of Chronic Myeloid Leukemia is 4.2 cases per 100,000. In addition to that, Chronic Myeloid Leukemia represents only 5% of all childhood leukemia. It is also reported that 85-90% of patients are diagnosed in the chronic phase.

• The disease epidemiology covered in the report provides historical as well as forecasted Chronic Myeloid Leukemia epidemiology [segmented as Total Incident Cases of Chronic Myeloid Leukemia, Total Symptomatic Cases of Chronic Myeloid Leukemia, Cases of Chronic Myeloid Leukemia by Phases (Chronic, Accelerated, and Blast), Age-specific Cases of Chronic Myeloid Leukemia, and Mutation-specific Cases of Chronic Myeloid Leukemia] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Chronic Myeloid Leukemia Epidemiology

This section provides glimpse of the Chronic Myeloid Leukemia epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Learn more about the evolving epidemiology trends and key developments: Chronic Myeloid Leukemia Epidemiology Forecast

Chronic Myeloid Leukemia Drug Chapters

The drug chapter segment of the Chronic Myeloid Leukemia report encloses the detailed analysis of Chronic Myeloid Leukemia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Chronic Myeloid Leukemia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Chronic Myeloid Leukemia Marketed Drugs

SCEMBLIX (asciminib): Novartis

In March 2022, SCEMBLIX was approved for Chronic Myeloid Leukemia in Japan. Its novel mechanism of action, also known in scientific literature as a STAMP inhibitor, may help address resistance in patients with CML previously treated with two or more TKIs and overcome mutations at the defective BCR-ABL1 gene, which is associated with the over-production of leukemic cells.

ICLUSIG (ponatinib): Takeda

In December 2012, the US FDA approved ICLUSIG for the treatment of adult patients with Chronic Myeloid Leukemia. ICLUSIG is a kinase inhibitor targeting BCR-ABL1, an abnormal tyrosine kinase that is expressed in CML and Ph+ ALL. ICLUSIG is a targeted cancer medicine developed using a computational and structure-based drug-design platform, specifically designed to inhibit the activity of BCR-ABL1 and its mutations.

TASIGNA (nilotinib): Novartis

It is approved in more than 122 countries for the treatment of chronic phase and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in adult patients resistant or intolerant to at least one prior therapy. In November 2017, Novartis announced that the European Commission (EC) approved Tasigna for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP) and pediatric patients with Ph+ CML-CP with resistance or intolerance to prior therapy including imatinib.

BOSULIF (bosutinib): Pfizer

In December 2017, the US FDA granted accelerated approval to BOSULIF (bosutinib) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).

SPRYCEL (dasatinib): Bristol-Myers Squibb

In November 2017, the US FDA granted regular approval to SPRYCEL (dasatinib), for the treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.

Other FDA approved drugs for the treatment of CML include GLEEVEC (imatinib), SYNRIBO (omacetaxine mepesuccinate), and others.

Note: Detailed Current therapies assessment will be provided in the full report of Chronic Myeloid Leukemia

Chronic Myeloid Leukemia Emerging Drugs

HQP1351, being developed by Ascentage Pharma, is an orally active, third-generation BCR-ABL inhibitor. It has been granted Orphan Drug Designation by the US FDA and the European Commission for the treatment of chronic myeloid leukemia.

TERN-701 is Terns’ proprietary, allosteric BCR-ABL TKI, designed to target the ABL myristoyl pocket, which is in development for the treatment of chronic myeloid leukemia (CML), a form of cancer that begins in the bone marrow. The drug was designed to achieve improved tumor suppression against a broader range of mutations, an enhanced pharmacokinetic profile with an increased half-life, and simplified dosing.

Note: Detailed emerging therapies assessment will be provided in the full report of Chronic Myeloid Leukemia

Chronic Myeloid Leukemia Market Outlook

There are various treatment options for CML based on fairly slow growing leukemia and the rate of cancer growth. With modern treatments, it's often possible to control chronic myeloid leukaemia (CML) for many years. In a small number of cases, it may be possible to cure it completely.

The treatment of CML includes Tyrosine kinase inhibitors, chemotherapy, radiation therapy, interferon therapy, and stem cell transplant. Radiation is seldom part of the treatment for patients with chronic myeloid leukemia (CML), but it might be used in certain situations.

Key players such as Denovo Biopharma, Orbus Therapeutics, Onconeutics, Celgene, Oblato and various others are involved in developing therapies for Chronic Myeloid Leukemia.

The dynamics of CML market is anticipated to change in the coming years owing to the improvement in the research and development undertaking. There are several key players involved in developing the therapies for CMML like Novartis, Ascentage Pharma, Terns Pharmaceuticals, Sanofi, Enliven Therapeutics, Kartos Therapeutics, and so on.

According to DelveInsight, Chronic Myeloid Leukemia market in 7MM is expected to witness a major change in the study period 2019-2032.

Analyst Commentary

• The pipeline of Chronic Myeloid Leukemia is very robust, many potential therapies are being investigated for the treatment of Chronic Myeloid Leukemia, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.

• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Chronic Myeloid Leukemia market in the 7MM. Aside from that, the market size of Chronic Myeloid Leukemia may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.

• The market growth of Chronic Myeloid Leukemia may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

Chronic Myeloid Leukemia Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Chronic Myeloid Leukemia market or expected to get launched in the market during the study period 2019-2032. The analysis covers Chronic Myeloid Leukemia market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Note: Detailed emerging therapies assessment will be provided in full report of Chronic Myeloid Leukemia.

Chronic Myeloid Leukemia Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Chronic Myeloid Leukemia key players involved in developing targeted therapeutics.

Chronic Myeloid Leukemia Clinical Trial Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Chronic Myeloid Leukemia emerging therapies.

Learn more about the emerging therapies and key companies active in the therapeutics segment: Chronic Myeloid Leukemia Pipeline Insight

Reimbursement Scenario in Chronic Myeloid Leukemia

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Chronic Myeloid Leukemia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic Myeloid Leukemia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Chronic Myeloid Leukemia Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Chronic Myeloid Leukemia Market Report

• The report covers the descriptive overview of Chronic Myeloid Leukemia, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the Chronic Myeloid Leukemia epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Myeloid Leukemia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Chronic Myeloid Leukemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• Detailed Patient Based Market Forecasting determines the trends shaping and driving the Global Chronic Myeloid Leukemia market

Chronic Myeloid Leukemia Market Report Highlights

• In the coming years, the Chronic Myeloid Leukemia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Myeloid Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Chronic Myeloid Leukemia. The launch of emerging therapies will significantly impact the Chronic Myeloid Leukemia market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chronic Myeloid Leukemia
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed Chronic Myeloid Leukemia clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chronic Myeloid Leukemia Report Insights

• Patient Based Market Forecasting
• Therapeutic Approaches
• Chronic Myeloid Leukemia Pipeline Analysis
• Chronic Myeloid Leukemia Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Chronic Myeloid Leukemia Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Chronic Myeloid Leukemia Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Chronic Myeloid Leukemia Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights:

• What was the Chronic Myeloid Leukemia drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Chronic Myeloid Leukemia total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest Chronic Myeloid Leukemia market size during the forecast period (2019-2032)?
• At what CAGR, the Chronic Myeloid Leukemia market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Chronic Myeloid Leukemia market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Chronic Myeloid Leukemia market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Chronic Myeloid Leukemia?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Chronic Myeloid Leukemia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Chronic Myeloid Leukemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Chronic Myeloid Leukemia?
• Out of all 7MM countries, which country would have the highest incident population of Chronic Myeloid Leukemia during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the Chronic Myeloid Leukemia treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Chronic Myeloid Leukemia in the USA, Europe, and Japan?
• What are the Chronic Myeloid Leukemia marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Chronic Myeloid Leukemia?
• How many therapies are in-development by each company for Chronic Myeloid Leukemia treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Chronic Myeloid Leukemia treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Myeloid Leukemia therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Myeloid Leukemia and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Chronic Myeloid Leukemia?
• What are the global historical and forecasted markets of Chronic Myeloid Leukemia?

Reasons to buy

• The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Chronic Myeloid Leukemia market
• Organize sales and marketing efforts by identifying the best opportunities for Chronic Myeloid Leukemia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Chronic Myeloid Leukemia market
• To understand the future market competition in the Chronic Myeloid Leukemia market